Analgesics
Antiandrogens
Antihistamines
Budesonide
Colchicine
Conv. Plasma
Curcumin
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Monoclonals
Mpro inhibitors
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Quercetin
RdRp inhibitors
TMPRSS2 inh.
Thermotherapy
Vitamins
More

Other
Feedback
Home
 
next
study
previous
study
c19early.org COVID-19 treatment researchSelect treatment..Select..
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta
Ivermectin Meta
Thermotherapy Meta
Melatonin Meta
Metformin Meta

 

Reduction in the COVID-19 pneumonia case fatality rate by silver nanoparticles: A randomized case study

Wieler et al., Heliyon, doi:10.1016/j.heliyon.2023.e14419, CTRI/2021/09/036781, Mar 2023
https://c19early.org/wieler.html
Mortality 56% Improvement Relative Risk Agnp  Wieler et al.  LATE TREATMENT  RCT Is late treatment with AgNP beneficial for COVID-19? RCT 40 patients in India (June 2021 - January 2022) Lower mortality with AgNP (p=0.0095) c19early.org Wieler et al., Heliyon, March 2023 FavorsAgNP Favorscontrol 0 0.5 1 1.5 2+
RCT 40 late stage hospitalized COVID-19 patients on oxygen showing significantly higher survival rates with intravenous silver nanoparticles (AgNPs). Authors suggest that antiviral, anti-inflammatory, antiplatelet, and antimicrobial properties may explain the observed benefits.
risk of death, 56.2% lower, RR 0.44, p = 0.010, treatment 7 of 20 (35.0%), control 16 of 20 (80.0%), NNT 2.2, day 30.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Wieler et al., 31 Mar 2023, Randomized Controlled Trial, India, peer-reviewed, mean age 69.5, 4 authors, study period June 2021 - January 2022, trial CTRI/2021/09/036781. Contact: s.sarkar735@gmail.com.
Reduction in the COVID-19 pneumonia case fatality rate by silver nanoparticles: A randomized case study
Laura Wieler, Oana Vittos, Nirmalya Mukherjee, Subhasish Sarkar
Heliyon, doi:10.1016/j.heliyon.2023.e14419
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), has devastated mankind. To date, no approved treatment is available to completely combat this disease. Although many studies reported the potential of silver nanoparticles' (AgNPs) action mechanism and effect against SARS-CoV-2, this is the first clinical trial that aimed to prove this effect. This open-label, randomized, parallel-group, investigator-initiated study (IIS) was conducted in India from 2021 to 2022 and included 40 patients diagnosed with moderately-severe to severe COVID-19 pneumonia. This study proved a significantly higher survival rates (p < 0.05) and significantly lower number of days until supplemental oxygenation was required (p < 0.0001) for patients receiving intravenous AgNPs in form of AgSept® in addition to the standard COVID-19 treatment. This study highlights the importance of intravenous AgNPs administration in the treatment of virus-induced pneumonia.
Declaration of interest's statement The authors declare the following conflict of interests. Financial competing interest: The author LW is employed at the company BHS Medical Solutions GmbH that sponsored the material AgSept® in the clinical trial. The author LW declares that she was not involved neither in the clinical trial, nor the statistical analysis of the data. The company BHS Medical Solution has filed an application for a patent correlated to this issue.
References
Allawadhi, Silver nanoparticle based multifunctional approach for combating COVID-19, Sensors Int
Atzrodt, A Guide to COVID-19: a Global Pandemic Caused by the Novel Coronavirus SARS-CoV-2, doi:10.1111/febs.15375
Bahrami, An overview of current drugs and prophylactic vaccines for coronavirus disease 2019 (COVID-19), Cell. Mol. Biol. Lett
Banach, Tymczyna, Chmielowiec-Korzeniowska, Pulit-Prociak, Nanosilver biocidal properties and their application in disinfection of hatchers in poultry processing plants, Bioinorgan. Chem. Appl
Cho, Nanoparticle Characterization: State of the Art, Challenges, and Emerging Technologies, doi:10.1021/mp300697h
Cr, Vanidassane, Pownraj, Kandasamy, Basheerid, National Early Warning Score 2 (NEWS2) to Predict Poor Outcome in Hospitalised COVID-19 Patients in India, doi:10.1371/journal.pone.0261376
Dhand, Li, PULMONARY PERSPECTIVE Coughs and Sneezes: Their Role in Transmission of Respiratory Viral Infections, Including SARS-CoV-2, doi:10.1164/rccm.202004-1263PP
Dheyab, Focused role of nanoparticles against COVID-19: diagnosis and treatment, Photodiagnosis Photodyn. Ther
Ferdous, Nemmar, Health impact of silver nanoparticles: a review of the biodistribution and toxicity following various routes of exposure, Int. J. Mol. Sci
Gurunathan, Antiviral potential of nanoparticles-can nanoparticles fight against coronaviruses?, Nanomaterials
Jeremiah, Miyakawa, Morita, Yamaoka, Ryo, Potent antiviral effect of silver nanoparticles on SARS-CoV-2, Biochem. Biophys. Res. Commun
Ji, Twenty-eight-day inhalation toxicity study of silver nanoparticles in Sprague-Dawley rats, Inhal. Toxicol
Jiang, Oberdörster, Biswas, Characterization of size, surface charge, and agglomeration state of nanoparticle dispersions for toxicological studies, J. Nanoparticle Res
Kaeley, Utility of early warning scores to predict mortality in COVID-19 patients: a retrospective observational study, Int. J. Crit. Illn. Inj. Sci
Kar, Exploring the potential of metal nanoparticles as a possible therapeutic adjunct for covid-19 infection, Proc. Natl. Acad. Sci. India B Biol. Sci, doi:10.1007/s40011-022-01371-1
Kostakis, The Performance of the National Early Warning Score and National Early Warning Score 2 in Hospitalised Patients Infected by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), doi:10.1016/j.resuscitation.2020.10.039
Kumar, Singh, Singh, Misra, Since January 2020 Elsevier Has Created a COVID-19 Resource Centre with Free Information in English and Mandarin on the Novel Coronavirus COVID-19
Morris, Antiviral and immunomodulatory activity of silver nanoparticles in experimental RSV infection, Viruses
Morris, Antiviral and immunomodulatory activity of silver nanoparticles in experimental RSV infection, Viruses
Muhammad, Zhai, Gao, Antiviral activity of nanomaterials against coronaviruses, Macromol. Biosci
Nair, Jacob, A simple practice guide for dose conversion between animals and human, J. Basic Clin. Pharm
Nikaeen, Abbaszadeh, Yousefinejad, Application of nanomaterials in treatment, anti-infection and detection of coronaviruses, Nanomedicine
Nuchin, Kumar, Mahesh, Predictors of mortality in patients with severe COVID-19 pneumonia-a retrospective study, Adv. Respir. Med
Organization, Worldometer, COVID-19 Coronavirus Pandemic
Pal, Tak, Song, Does the antibacterial activity of silver nanoparticles depend on the shape of the nanoparticle? A study of the gram-negative bacterium Escherichia coli, Appl. Environ. Microbiol
Parohan, Risk factors for mortality in patients with Coronavirus disease 2019 (COVID-19) infection: a systematic review and meta-analysis of observational studies, Aging Male
Ratan, Silver nanoparticles as potential antiviral agents, Pharmaceutics
Salleh, The potential of silver nanoparticles for antiviral and antibacterial applications: a mechanism of action, Nanomaterials
Sanchez-Guzman, Silver nanoparticle-adjuvanted vaccine protects against lethal influenza infection through inducing BALT and IgA-mediated mucosal immunity, Biomaterials
Sarkar, Das, Aich, Bhattacharyya, Acharya, Antiviral potential of nanoparticles for the treatment of Coronavirus infections, J. Trace Elem. Med. Biol
Sinha, Som Chaudhury, Sharma, Ruidas, COVID-19 rhapsody: rage towards advanced diagnostics and therapeutic strategy, J. Pharm. Anal
Speshock, Murdock, Braydich-Stolle, Schrand, Hussain, Interaction of silver nanoparticles with Tacaribe virus, J. Nanobiotechnol
Struyf, Jj, Dinnes, Takwoingi, Davenport, Cochrane Library Cochrane Database of Systematic Reviews Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID, Rev, doi:10.1002/14651858.CD013665.pub2
Torjesen, Covid-19: hydroxychloroquine does not benefit hospitalised patients, UK trial finds, BMJ, doi:10.1136/bmj.m2263
Veldhuis, Early warning scores to assess the probability of critical illness in patients with COVID-19, Emerg. Med. J
Wibisono, National early warning score (NEWS) 2 predicts hospital mortality from COVID-19 patients, Ann. Med. Surg
Xiang, Chen, Pang, Zheng, Inhibitory effects of silver nanoparticles on H1N1 influenza A virus in vitro, J. Virol. Methods
Xiang, Inhibition of A/Human/Hubei/3/2005 (H3N2) influenza virus infection by silver nanoparticles in vitro and in vivo, Int. J. Nanomed
Zachar, Formulations for COVID-19 early stage treatment via silver nanoparticles inhalation delivery at home and hospital, Sci. Prepr, doi:10.14293/S2199-1006.1.SOR-.PPHBJEO.v1
DOI record: { "DOI": "10.1016/j.heliyon.2023.e14419", "ISSN": [ "2405-8440" ], "URL": "http://dx.doi.org/10.1016/j.heliyon.2023.e14419", "alternative-id": [ "S2405844023016262" ], "article-number": "e14419", "assertion": [ { "label": "This article is maintained by", "name": "publisher", "value": "Elsevier" }, { "label": "Article Title", "name": "articletitle", "value": "Reduction in the COVID-19 pneumonia case fatality rate by silver nanoparticles: A randomized case study" }, { "label": "Journal Title", "name": "journaltitle", "value": "Heliyon" }, { "label": "CrossRef DOI link to publisher maintained version", "name": "articlelink", "value": "https://doi.org/10.1016/j.heliyon.2023.e14419" }, { "label": "Content Type", "name": "content_type", "value": "article" }, { "label": "Copyright", "name": "copyright", "value": "© 2023 The Authors. Published by Elsevier Ltd." } ], "author": [ { "affiliation": [], "family": "Wieler", "given": "Laura", "sequence": "first" }, { "affiliation": [], "family": "Vittos", "given": "Oana", "sequence": "additional" }, { "affiliation": [], "family": "Mukherjee", "given": "Nirmalya", "sequence": "additional" }, { "affiliation": [], "family": "Sarkar", "given": "Subhasish", "sequence": "additional" } ], "container-title": "Heliyon", "container-title-short": "Heliyon", "content-domain": { "crossmark-restriction": true, "domain": [ "cell.com", "elsevier.com", "sciencedirect.com" ] }, "created": { "date-parts": [ [ 2023, 3, 11 ] ], "date-time": "2023-03-11T21:44:10Z", "timestamp": 1678571050000 }, "deposited": { "date-parts": [ [ 2025, 4, 16 ] ], "date-time": "2025-04-16T03:18:06Z", "timestamp": 1744773486000 }, "indexed": { "date-parts": [ [ 2025, 4, 16 ] ], "date-time": "2025-04-16T03:40:01Z", "timestamp": 1744774801009, "version": "3.40.4" }, "is-referenced-by-count": 12, "issue": "3", "issued": { "date-parts": [ [ 2023, 3 ] ] }, "journal-issue": { "issue": "3", "published-print": { "date-parts": [ [ 2023, 3 ] ] } }, "language": "en", "license": [ { "URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "content-version": "tdm", "delay-in-days": 0, "start": { "date-parts": [ [ 2023, 3, 1 ] ], "date-time": "2023-03-01T00:00:00Z", "timestamp": 1677628800000 } }, { "URL": "https://www.elsevier.com/legal/tdmrep-license", "content-version": "tdm", "delay-in-days": 0, "start": { "date-parts": [ [ 2023, 3, 1 ] ], "date-time": "2023-03-01T00:00:00Z", "timestamp": 1677628800000 } }, { "URL": "http://creativecommons.org/licenses/by-nc-nd/4.0/", "content-version": "vor", "delay-in-days": 5, "start": { "date-parts": [ [ 2023, 3, 6 ] ], "date-time": "2023-03-06T00:00:00Z", "timestamp": 1678060800000 } } ], "link": [ { "URL": "https://api.elsevier.com/content/article/PII:S2405844023016262?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://api.elsevier.com/content/article/PII:S2405844023016262?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining" } ], "member": "78", "original-title": [], "page": "e14419", "prefix": "10.1016", "published": { "date-parts": [ [ 2023, 3 ] ] }, "published-print": { "date-parts": [ [ 2023, 3 ] ] }, "publisher": "Elsevier BV", "reference": [ { "key": "10.1016/j.heliyon.2023.e14419_bib1", "unstructured": "Organization, W. health. Worldometer. COVID-19 Coronavirus Pandemic. https://www.worldometers.info/coronavirus/." }, { "DOI": "10.1016/j.jpha.2021.06.004", "article-title": "COVID-19 rhapsody: rage towards advanced diagnostics and therapeutic strategy", "author": "Sinha", "doi-asserted-by": "crossref", "first-page": "529", "journal-title": "J. Pharm. Anal.", "key": "10.1016/j.heliyon.2023.e14419_bib2", "volume": "11", "year": "2021" }, { "author": "Dhand", "key": "10.1016/j.heliyon.2023.e14419_bib3", "series-title": "PULMONARY PERSPECTIVE Coughs and Sneezes: Their Role in Transmission of Respiratory Viral Infections, Including SARS-CoV-2", "year": "2020" }, { "DOI": "10.1111/febs.15375", "doi-asserted-by": "crossref", "key": "10.1016/j.heliyon.2023.e14419_bib4", "unstructured": "Atzrodt, C. L. et al. A Guide to COVID-19: a Global Pandemic Caused by the Novel Coronavirus SARS-CoV-2. doi:10.1111/febs.15375." }, { "article-title": "Cochrane Library Cochrane Database of Systematic Reviews Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID", "author": "Struyf", "journal-title": "Rev.", "key": "10.1016/j.heliyon.2023.e14419_bib5", "volume": "19", "year": "2021" }, { "DOI": "10.1080/13685538.2020.1774748", "article-title": "Risk factors for mortality in patients with Coronavirus disease 2019 (COVID-19) infection: a systematic review and meta-analysis of observational studies", "author": "Parohan", "doi-asserted-by": "crossref", "first-page": "1416", "journal-title": "Aging Male", "key": "10.1016/j.heliyon.2023.e14419_bib6", "volume": "23", "year": "2020" }, { "DOI": "10.4103/ijciis.ijciis_64_21", "article-title": "Utility of early warning scores to predict mortality in COVID-19 patients: a retrospective observational study", "author": "Kaeley", "doi-asserted-by": "crossref", "first-page": "163", "journal-title": "Int. J. Crit. Illn. Inj. Sci.", "key": "10.1016/j.heliyon.2023.e14419_bib7", "volume": "11", "year": "2021" }, { "DOI": "10.5603/ARM.a2021.0036", "article-title": "Predictors of mortality in patients with severe COVID-19 pneumonia—a retrospective study", "author": "Nuchin", "doi-asserted-by": "crossref", "first-page": "135", "journal-title": "Adv. Respir. Med.", "key": "10.1016/j.heliyon.2023.e14419_bib8", "volume": "89", "year": "2021" }, { "DOI": "10.1186/s11658-022-00339-3", "article-title": "An overview of current drugs and prophylactic vaccines for coronavirus disease 2019 (COVID-19)", "author": "Alagheband Bahrami", "doi-asserted-by": "crossref", "first-page": "38", "journal-title": "Cell. Mol. Biol. Lett.", "key": "10.1016/j.heliyon.2023.e14419_bib9", "volume": "27", "year": "2022" }, { "key": "10.1016/j.heliyon.2023.e14419_bib10", "unstructured": "World health organization. World Health Organization. International Clinical Trials Registry Platform (ICTRP). https://www.who.int/ictrp/en/." }, { "article-title": "Covid-19: hydroxychloroquine does not benefit hospitalised patients, UK trial finds", "author": "Torjesen", "journal-title": "BMJ", "key": "10.1016/j.heliyon.2023.e14419_bib11", "volume": "m2263", "year": "2020" }, { "author": "Kumar", "key": "10.1016/j.heliyon.2023.e14419_bib12", "series-title": "Since January 2020 Elsevier Has Created a COVID-19 Resource Centre with Free Information in English and Mandarin on the Novel Coronavirus COVID- 19 . The COVID-19 Resource Centre Is Hosted", "year": "2020" }, { "DOI": "10.1007/s40011-022-01371-1", "article-title": "Exploring the potential of metal nanoparticles as a possible therapeutic adjunct for covid-19 infection", "author": "Kar", "doi-asserted-by": "crossref", "journal-title": "Proc. Natl. Acad. Sci. India B Biol. Sci.", "key": "10.1016/j.heliyon.2023.e14419_bib13", "year": "2022" }, { "DOI": "10.2217/nnm-2020-0117", "article-title": "Application of nanomaterials in treatment, anti-infection and detection of coronaviruses", "author": "Nikaeen", "doi-asserted-by": "crossref", "first-page": "1501", "journal-title": "Nanomedicine", "key": "10.1016/j.heliyon.2023.e14419_bib14", "volume": "15", "year": "2020" }, { "DOI": "10.1002/mabi.202000196", "article-title": "Antiviral activity of nanomaterials against coronaviruses", "author": "Muhammad", "doi-asserted-by": "crossref", "first-page": "1", "journal-title": "Macromol. Biosci.", "key": "10.1016/j.heliyon.2023.e14419_bib15", "volume": "20", "year": "2020" }, { "DOI": "10.1007/s11051-008-9446-4", "article-title": "Characterization of size, surface charge, and agglomeration state of nanoparticle dispersions for toxicological studies", "author": "Jiang", "doi-asserted-by": "crossref", "first-page": "77", "journal-title": "J. Nanoparticle Res.", "key": "10.1016/j.heliyon.2023.e14419_bib16", "volume": "11", "year": "2009" }, { "DOI": "10.1021/mp300697h", "doi-asserted-by": "crossref", "key": "10.1016/j.heliyon.2023.e14419_bib17", "unstructured": "Cho, E. J. et al. Nanoparticle Characterization: State of the Art, Challenges, and Emerging Technologies. doi:10.1021/mp300697h." }, { "DOI": "10.1128/AEM.02218-06", "article-title": "Does the antibacterial activity of silver nanoparticles depend on the shape of the nanoparticle? A study of the gram-negative bacterium Escherichia coli", "author": "Pal", "doi-asserted-by": "crossref", "first-page": "1712", "journal-title": "Appl. Environ. Microbiol.", "key": "10.1016/j.heliyon.2023.e14419_bib18", "volume": "73", "year": "2007" }, { "DOI": "10.1016/j.jtemb.2022.126977", "article-title": "Antiviral potential of nanoparticles for the treatment of Coronavirus infections", "author": "Sarkar", "doi-asserted-by": "crossref", "journal-title": "J. Trace Elem. Med. Biol.", "key": "10.1016/j.heliyon.2023.e14419_bib19", "volume": "72", "year": "2022" }, { "DOI": "10.3390/pharmaceutics13122034", "article-title": "Silver nanoparticles as potential antiviral agents", "author": "Ratan", "doi-asserted-by": "crossref", "first-page": "1", "journal-title": "Pharmaceutics", "key": "10.1016/j.heliyon.2023.e14419_bib20", "volume": "13", "year": "2021" }, { "DOI": "10.1186/1477-3155-8-19", "article-title": "Interaction of silver nanoparticles with Tacaribe virus", "author": "Speshock", "doi-asserted-by": "crossref", "first-page": "1", "journal-title": "J. Nanobiotechnol.", "key": "10.1016/j.heliyon.2023.e14419_bib21", "volume": "8", "year": "2010" }, { "DOI": "10.3390/v11080732", "article-title": "Antiviral and immunomodulatory activity of silver nanoparticles in experimental RSV infection", "author": "Morris", "doi-asserted-by": "crossref", "journal-title": "Viruses", "key": "10.1016/j.heliyon.2023.e14419_bib22", "volume": "11", "year": "2019" }, { "DOI": "10.3390/nano10081566", "article-title": "The potential of silver nanoparticles for antiviral and antibacterial applications: a mechanism of action", "author": "Salleh", "doi-asserted-by": "crossref", "first-page": "1566", "journal-title": "Nanomaterials", "key": "10.1016/j.heliyon.2023.e14419_bib23", "volume": "10", "year": "2020" }, { "DOI": "10.1016/j.sintl.2021.100101", "article-title": "Silver nanoparticle based multifunctional approach for combating COVID-19", "author": "Allawadhi", "doi-asserted-by": "crossref", "journal-title": "Sensors Int", "key": "10.1016/j.heliyon.2023.e14419_bib24", "volume": "2", "year": "2021" }, { "DOI": "10.1016/j.jviromet.2011.09.003", "article-title": "Inhibitory effects of silver nanoparticles on H1N1 influenza A virus in vitro", "author": "Xiang", "doi-asserted-by": "crossref", "first-page": "137", "journal-title": "J. Virol. Methods", "key": "10.1016/j.heliyon.2023.e14419_bib25", "volume": "178", "year": "2011" }, { "DOI": "10.2147/IJN.S53622", "article-title": "Inhibition of A/Human/Hubei/3/2005 (H3N2) influenza virus infection by silver nanoparticles in vitro and in vivo", "author": "Xiang", "doi-asserted-by": "crossref", "first-page": "4103", "journal-title": "Int. J. Nanomed.", "key": "10.1016/j.heliyon.2023.e14419_bib26", "volume": "8", "year": "2013" }, { "DOI": "10.1016/j.bbrc.2020.09.018", "article-title": "Potent antiviral effect of silver nanoparticles on SARS-CoV-2", "author": "Jeremiah", "doi-asserted-by": "crossref", "first-page": "195", "journal-title": "Biochem. Biophys. Res. Commun.", "key": "10.1016/j.heliyon.2023.e14419_bib27", "volume": "533", "year": "2020" }, { "DOI": "10.3390/ijms21072375", "article-title": "Health impact of silver nanoparticles: a review of the biodistribution and toxicity following various routes of exposure", "author": "Ferdous", "doi-asserted-by": "crossref", "journal-title": "Int. J. Mol. Sci.", "key": "10.1016/j.heliyon.2023.e14419_bib28", "volume": "21", "year": "2020" }, { "DOI": "10.1080/08958370701432108", "article-title": "Twenty-eight-day inhalation toxicity study of silver nanoparticles in Sprague-Dawley rats", "author": "Ji", "doi-asserted-by": "crossref", "first-page": "857", "journal-title": "Inhal. Toxicol.", "key": "10.1016/j.heliyon.2023.e14419_bib29", "volume": "19", "year": "2007" }, { "DOI": "10.3390/v11080732", "article-title": "Antiviral and immunomodulatory activity of silver nanoparticles in experimental RSV infection", "author": "Morris", "doi-asserted-by": "crossref", "journal-title": "Viruses", "key": "10.1016/j.heliyon.2023.e14419_bib30", "volume": "11", "year": "2019" }, { "DOI": "10.1016/j.biomaterials.2019.119308", "article-title": "Silver nanoparticle-adjuvanted vaccine protects against lethal influenza infection through inducing BALT and IgA-mediated mucosal immunity", "author": "Sanchez-Guzman", "doi-asserted-by": "crossref", "journal-title": "Biomaterials", "key": "10.1016/j.heliyon.2023.e14419_bib31", "volume": "217", "year": "2019" }, { "article-title": "Nanosilver biocidal properties and their application in disinfection of hatchers in poultry processing plants", "author": "Banach", "journal-title": "Bioinorgan. Chem. Appl.", "key": "10.1016/j.heliyon.2023.e14419_bib32", "volume": "2016", "year": "2016" }, { "article-title": "Formulations for COVID-19 early stage treatment via silver nanoparticles inhalation delivery at home and hospital", "author": "Zachar", "first-page": "1", "journal-title": "Sci. Prepr.", "key": "10.1016/j.heliyon.2023.e14419_bib33", "year": "2020" }, { "DOI": "10.1016/j.amsu.2022.103462", "article-title": "National early warning score (NEWS) 2 predicts hospital mortality from COVID-19 patients", "author": "Wibisono", "doi-asserted-by": "crossref", "journal-title": "Ann. Med. Surg.", "key": "10.1016/j.heliyon.2023.e14419_bib34", "volume": "76", "year": "2022" }, { "author": "Cr", "key": "10.1016/j.heliyon.2023.e14419_bib35", "series-title": "National Early Warning Score 2 (NEWS2) to Predict Poor Outcome in Hospitalised COVID-19 Patients in India", "year": "2021" }, { "author": "Kostakis", "key": "10.1016/j.heliyon.2023.e14419_bib36", "series-title": "The Performance of the National Early Warning Score and National Early Warning Score 2 in Hospitalised Patients Infected by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)", "year": "2020" }, { "DOI": "10.1136/emermed-2020-211054", "article-title": "Early warning scores to assess the probability of critical illness in patients with COVID-19", "author": "Veldhuis", "doi-asserted-by": "crossref", "first-page": "901", "journal-title": "Emerg. Med. J.", "key": "10.1016/j.heliyon.2023.e14419_bib37", "volume": "38", "year": "2021" }, { "DOI": "10.4103/0976-0105.177703", "article-title": "A simple practice guide for dose conversion between animals and human", "author": "Nair", "doi-asserted-by": "crossref", "first-page": "27", "journal-title": "J. Basic Clin. Pharm.", "key": "10.1016/j.heliyon.2023.e14419_bib38", "volume": "7", "year": "2016" }, { "DOI": "10.1016/j.pdpdt.2021.102287", "article-title": "Focused role of nanoparticles against COVID-19: diagnosis and treatment", "author": "Dheyab", "doi-asserted-by": "crossref", "journal-title": "Photodiagnosis Photodyn. Ther.", "key": "10.1016/j.heliyon.2023.e14419_bib39", "volume": "34", "year": "2021" }, { "DOI": "10.3390/nano10091645", "article-title": "Antiviral potential of nanoparticles—can nanoparticles fight against coronaviruses?", "author": "Gurunathan", "doi-asserted-by": "crossref", "first-page": "1", "journal-title": "Nanomaterials", "key": "10.1016/j.heliyon.2023.e14419_bib40", "volume": "10", "year": "2020" } ], "reference-count": 40, "references-count": 40, "relation": {}, "resource": { "primary": { "URL": "https://linkinghub.elsevier.com/retrieve/pii/S2405844023016262" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [], "subtitle": [], "title": "Reduction in the COVID-19 pneumonia case fatality rate by silver nanoparticles: A randomized case study", "type": "journal-article", "update-policy": "https://doi.org/10.1016/elsevier_cm_policy", "volume": "9" }
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 200,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
  or use drag and drop   
Submit